• Explore /
  • Poster
  • / Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.

Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.

Abstract Poster

Authors

Nabil Saba

Nabil F. Saba

Winship Cancer Institute, Emory University, Atlanta, GA

Nabil F. Saba , George R. Blumenschein Jr., Joel Guigay , Lisa F. Licitra , Jerome Fayette , Kevin J. Harrington , Naomi Kiyota , Maura L. Gillison , Robert L. Ferris , Vijayvel Jayaprakash , Mark John Lynch , Li Li , Peter Brossart

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02105636

Citation

J Clin Oncol 36, 2018 (suppl; abstr 6028)

DOI

10.1200/JCO.2018.36.15_suppl.6028

Abstract #

6028

Poster Bd #

16

Abstract Disclosures

Similar Posters

First Author: Robert L. Ferris

First Author: Maura L. Gillison

First Author: Kate Carroll

First Author: A. Dimitrios Dimitrios Colevas